After numerous high-profile safety scares, clinicians and regulators push to fix critical weaknesses in the FDA’s monitoring system for approved drugs.
Bio Business
Most Recent
Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.
The surprising results when drug development and altruism collide
Page 1 of 1
Subjects
- biobusiness
- biotech
- business
- cancer
- cell & molecular biology
- clinical trials
- disease/medicine
- drug development
- FDA
- regulation
Sub Categories
- Bio Business
- Capsule Reviews
- Careers
- Contributors
- Critic At Large
- Editorial
- Features
- Foundations
- Lab Tools
- Modus Operandi
- Notebook
- Profile
- Reading Frames
- Scientist to Watch
- Speaking of Science
- The Literature
- Thought Experiment
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
